Retatrutide is a novel therapeutic/treatment/medicine agent under investigation for the management/treatment/control of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists/glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide agonists, which work by stimulating/activating/enhancing the r

Arriving in the arena of weight management management, retatrutide represents a different approach. Different from many current medications, retatrutide functions as a double agonist, concurrently engaging both GLP peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) sensors. The simultaneous activation encourages several benefi